Drug
Adavosertib clinical trials
Also written AZD1775 and MK-1775.
- studies test it
- 50
- open now
- 1
- in phase 3
- 0
- first study started
- 2010
Keep track of what changes. Save the adavosertib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
50 studies that test it; most in 2015 (13)
| Year | Studies |
|---|---|
| 2010 | 3 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 8 |
| 2015 | 13 |
| 2016 | 6 |
| 2017 | 3 |
| 2018 | 5 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 3 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 24
- Phase 2
- 28
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 17 · Other 33
National Cancer Institute (NCI) (16) · AstraZeneca (14) · Merck Sharp & Dohme LLC (3) · Samsung Medical Center (3) · M.D. Anderson Cancer Center (2) · Dana-Farber Cancer Institute (2) · Canadian Cancer Trials Group (1) · H. Lee Moffitt Cancer Center and Research Institute (1)
Often tested with
Tested in the same studies.
Carboplatin (7) · Olaparib (6) · Cisplatin (5) · Ceralasertib (4) · Paclitaxel (4) · Capivasertib (3) · Irinotecan (3) · AZD4547 (2)
Studies
Open first, then newest update. How each study uses adavosertib is read from its arms, and is right about nine times in ten.
Testing it · 50
- European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsRecruitingPhase 1/2Gustave Roussy, Cancer Campus, Grand ParisNCT02813135Written as Adavosertib
- Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2Active, not recruitingPhase 2National Cancer Institute (NCI)NCT03284385Written as Adavosertib
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT02465060Written as Adavosertib
- To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.Active, not recruitingPhase 2AstraZenecaNCT03330847Written as Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).
- Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT04439227Written as Adavosertib
- Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal CancerActive, not recruitingEarly Phase 1M.D. Anderson Cancer CenterNCT02659241Written as Adavosertib
- Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder CancerActive, not recruitingPhase 1AstraZenecaNCT02546661Written as AZD1775
- Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR StudyActive, not recruitingPhase 1National Cancer Institute (NCI)NCT04197713Written as Adavosertib
- AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine CarcinosarcomaActive, not recruitingPhase 2Dana-Farber Cancer InstituteNCT03668340Written as AZD1775
- Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingPhase 2National Cancer Institute (NCI)NCT02101775Written as Adavosertib
- Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction CancersActive, not recruitingPhase 1National Cancer Institute (NCI)NCT04460937Written as Adavosertib
- Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT03579316Written as Adavosertib
- Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid TumoursCompletedPhase 1AstraZenecaNCT02617277Written as AZD1775
- AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung CancerCompletedPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT02513563Written as AZD1775
- Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid LeukemiaTerminatedPhase 1National Cancer Institute (NCI)NCT02381548Written as Adavosertib
- Prostate Cancer Biomarker Enrichment and Treatment SelectionActive, not recruitingPhase 2Canadian Cancer Trials GroupNCT03385655Written as Adavosertib
- A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung CancerCompletedPhase 2AstraZenecaNCT02937818Written as AZD1775 and carboplatin (CBPT)
- Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine CancersTerminatedPhase 1National Cancer Institute (NCI)NCT03345784Written as Adavosertib
- Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine GliomasCompletedPhase 1National Cancer Institute (NCI)NCT01922076Written as Adavosertib
- AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 AmplificationCompletedPhase 2National Cancer Institute (NCI)NCT03253679Written as Adavosertib
See all 50 studies that test adavosertib →
Given in every arm · 7 — adavosertib is usual care beside what is tested
- Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent GlioblastomaCompletedPhase 1National Cancer Institute (NCI)NCT01849146Written as Adavosertib
- WEE1 Inhibitor with Cisplatin and Radiotherapy: a Trial in Head and Neck CancerCompletedPhase 1University of BirminghamNCT03028766Written as AZD1775
- Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedPhase 2AstraZenecaNCT02272790Written as Adavosertib
- A Dose Escalation Study of Adavosertib (MK-1775) in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001)CompletedPhase 1Merck Sharp & Dohme LLCNCT00648648Written as adavosertib
- A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of AdavosertibTerminatedPhase 1AstraZenecaNCT04959266Written as Adavosertib
- Dose Escalation Trial of AZD1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the PancreasCompletedPhase 1/2University of Michigan Rogel Cancer CenterNCT02037230Written as MK-1775
- WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedPhase 2Mayo ClinicNCT02666950Written as WEE1 Inhibitor AZD1775
As the comparator · 1 — what is tested is compared with adavosertib
Codes
What other systems call adavosertib · ClinicalTrials.gg INT005632
- MeSH (NLM) C549567adavosertibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) K2T6HJX3I3ADAVOSERTIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27074716adavosertibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C91725AdavosertibOne source FDA
- DrugBank DB11740One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C549567 | adavosertib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | K2T6HJX3I3 | ADAVOSERTIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27074716 | adavosertib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C91725 | Adavosertib | One source FDA |
| DrugBank | DB11740 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.